ODYSSEY THERAPEUTICS INC (ODTX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-16

$17.17-2.28%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 16, 2026

What could strengthen or challenge ODYSSEY THERAPEUTICS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain sufficient cash runway into second half of 2028	A supporting condition in ODYSSEY THERAPEUTICS INC's published investment case. The stated target is Cash on hand of at least $433.1 million.	Intact	Cash on hand falls below $300 million	Cash and cash equivalents: $82.031M FY2026-Q2; GAAP. Published target: Cash on hand of at least $433.1 million. The target does not explicitly identify fiscal versus calendar quarters. Source date unavailable82,031,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_balance_sheet. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Cash and equivalents increased from $175.7 million plus $288.7 million IPO proceeds in 2026-Q1 to $433.1 million in 2026-Q2, supporting the expected runway into the second half of 2028. Management is delivering on maintaining sufficient cash runway. Delivery assessment Oct 16, 2026
Advance clinical development of OD-001 and OD-002	A primary condition in ODYSSEY THERAPEUTICS INC's published investment case. The stated target is Complete Phase 2b trials for OD-001 and initiate Phase 1/2a trials for OD-002 by end of 2026.	Improving	Clinical trials for OD-001 and OD-002 do not progress as planned	Qualitative: Trials extended by 2 years September 2026 news reports Odyssey banks two more years as trials multiply, strongly reinforcing clinical development objectives. Context reviewed through Oct 15, 2026Last status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management emphasized initiating Phase 2b monotherapy and Phase 2a combination trials for OD-001 in 2H 2026 and filing a CTA for OD-002 by end of 2026. Cash on hand was $433.1 million as of 2026-Q2, expected to fund operations into the second half of 2028. The trajectory is delivering with clinical milestones planned and cash runway secured. Delivery assessment Oct 16, 2026
Manage operating expenses to control cash burn	A supporting condition in ODYSSEY THERAPEUTICS INC's published investment case. The stated target is R&D expenses below $40 million and G&A expenses below $10 million.	Intact	R&D expenses exceed $40 million or G&A expenses exceed $10 million	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. R&D expenses rose from $30.2 million in 2025-Q2 to $36.2 million in 2026-Q2 due to advancing clinical programs, while G&A expenses decreased from $13.2 million to $10.5 million over the same period. Net losses increased to -$52.8 million in 2026-Q2. Management shows mixed progress controlling cash burn with increased R&D but reduced G&A. Delivery assessment Oct 16, 2026

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-4.68

Unavailable → $-4.68 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-08-03	Unavailable	$2,976,000	4 / 5
2026-08-04	Unavailable	$2,976,000	4 / 5
2026-08-05	Unavailable	$2,976,000	4 / 5
2026-08-06	Unavailable	$2,976,000	4 / 5
2026-08-07	Unavailable	Unavailable	4 / 4
2026-08-08	Unavailable	Unavailable	4 / 4
2026-08-09	Unavailable	Unavailable	4 / 4
2026-08-10	Unavailable	Unavailable	4 / 4
2026-08-12	Unavailable	Unavailable	4 / 4
2026-08-13	Unavailable	Unavailable	4 / 4
2026-08-14	Unavailable	Unavailable	4 / 4
2026-08-15	Unavailable	Unavailable	4 / 4
2026-08-16	Unavailable	Unavailable	4 / 4
2026-08-17	Unavailable	Unavailable	4 / 4
2026-08-18	Unavailable	Unavailable	4 / 4
2026-08-19	Unavailable	Unavailable	4 / 4
2026-08-20	Unavailable	$2,976,000	4 / 5
2026-08-21	Unavailable	$2,976,000	4 / 5
2026-08-22	Unavailable	$2,976,000	4 / 5
2026-08-23	Unavailable	$2,976,000	4 / 5
2026-08-24	Unavailable	$2,976,000	4 / 5
2026-08-25	Unavailable	$2,976,000	4 / 5
2026-08-26	Unavailable	$2,976,000	4 / 5
2026-08-27	Unavailable	$2,976,000	4 / 5
2026-08-28	Unavailable	$2,976,000	4 / 5
2026-08-29	Unavailable	$2,976,000	4 / 6
2026-08-30	$-4.87	$2,976,000	5 / 6
2026-08-31	$-4.87	$2,976,000	5 / 6
2026-09-01	$-4.87	$2,976,000	5 / 6
2026-09-02	$-4.87	$2,976,000	5 / 6
2026-09-03	$-4.87	$2,976,000	5 / 6
2026-09-04	$-4.87	$2,976,000	5 / 6
2026-09-05	$-4.87	$2,976,000	5 / 6
2026-09-06	$-4.87	$2,976,000	5 / 6
2026-09-07	$-4.87	$2,976,000	5 / 6
2026-09-08	$-4.87	$2,976,000	5 / 6
2026-09-09	$-4.87	$2,976,000	5 / 6
2026-09-10	$-4.87	$2,976,000	5 / 6
2026-09-11	$-4.87	$2,976,000	5 / 6
2026-09-12	$-4.87	$2,976,000	5 / 6
2026-09-13	$-4.87	$2,976,000	5 / 6
2026-09-14	$-4.87	$2,976,000	5 / 6
2026-09-15	$-4.87	$2,976,000	5 / 6
2026-09-16	$-4.87	$2,976,000	5 / 6
2026-09-17	$-4.87	$2,976,000	5 / 6
2026-09-18	$-4.87	$2,976,000	5 / 6
2026-09-19	$-4.87	$2,976,000	5 / 6
2026-09-20	$-4.87	$2,976,000	5 / 6
2026-09-21	$-4.87	$2,976,000	5 / 6
2026-09-22	$-4.87	$2,976,000	5 / 6
2026-09-23	$-4.87	$2,976,000	5 / 6
2026-09-24	$-4.87	$2,976,000	5 / 6
2026-09-25	$-4.87	$2,976,000	5 / 6
2026-09-26	$-4.87	$2,976,000	5 / 6
2026-09-27	$-4.87	$2,976,000	5 / 6
2026-09-28	$-4.87	$2,976,000	5 / 6
2026-09-29	$-4.87	$2,976,000	5 / 6
2026-09-30	$-4.87	$2,976,000	5 / 6
2026-10-01	Unavailable	$2,976,000	4 / 6
2026-10-02	Unavailable	$2,976,000	4 / 6
2026-10-03	Unavailable	$2,976,000	4 / 6
2026-10-04	Unavailable	$2,976,000	4 / 6
2026-10-05	Unavailable	$2,976,000	4 / 6
2026-10-06	Unavailable	$2,976,000	4 / 6
2026-10-07	Unavailable	$2,976,000	4 / 6
2026-10-08	Unavailable	$2,976,000	4 / 6
2026-10-09	Unavailable	$2,976,000	4 / 6
2026-10-10	Unavailable	$2,976,000	4 / 6
2026-10-11	Unavailable	$2,976,000	4 / 6
2026-10-12	$-4.87	$2,976,000	5 / 7
2026-10-13	$-4.67	$2,976,000	5 / 7
2026-10-14	$-4.68	$2,976,000	5 / 7
2026-10-15	$-4.68	$2,976,000	6 / 7
2026-10-16	$-4.68	$2,976,000	6 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-06-01	5	0	0
2026-07-01	5	0	0
2026-08-01	6	0	0
2026-09-01	6	0	0
2026-10-01	8	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 17–Oct 16 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 12

$27.00New observation · no comparable prior

Raymond JamesOct 8

$42.00New observation · no comparable prior

$0$23.10$46.20

0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 17, 2026–Oct 16, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain sufficient cash runway into second half of 2028Cash and cash equivalents: $82.031M
Manage operating expenses to control cash burnDirect metric needs a verified mapping

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.5%Typical daily move · historical

Downside history

-42.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

ODYSSEY THERAPEUTICS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a speculative growth opportunity. ODTX is focused on advancing its clinical programs while managing cash burn, but recent earnings misses have raised concerns about its near-term performance.

What's priced into ODYSSEY THERAPEUTICS INC

The market appears to have a low fragility tier, indicating that there are no immediate concerns about the stability of ODTX. However, the recent earnings misses suggest that expectations may be cautious, reflecting a wait-and-see approach from investors.

What the fundamentals likely do

Management has shown mixed progress in executing its priorities, particularly in advancing clinical trials and managing operating expenses. The elevated probability of a near-term earnings miss adds to the uncertainty surrounding ODTX's fundamental trajectory.

What ODYSSEY THERAPEUTICS INC hinges on

The long-term thesis hinges on the successful advancement of clinical trials for OD-001 and OD-002, as well as the broader healthcare sector's performance. Key triggers include guidance updates from ODTX and earnings results from sector leaders like VRTX, MRNA, and REGN.